Clinical Trial Update: Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing two doses of fulvestrant (250 mg vs 500 mg) in postmenopausal women with estrogen receptor–positive advanced breast cancer progressing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2010-06-15